EGFR has long been considered a potential therapeutic target for RA, as its activation primarily promotes synoviocyte proliferation and cytokine production, and EGFR activation is also an important mechanism by which cells resist apoptosis, which may contribute to FLS overproliferation (Yuan et al., 2013). The gene discussed is EGFR; the disease is rheumatoid arthritis.